Rob Dillard

DocwireNews

The SIRONA study demonstrated that MagicTouch™️ sirolimus-coated balloons are non-inferior compared to paclitaxel-coated balloons with respect to efficacy in patients with femoropopliteal artery disease. The findings were reported at TCT 2024.
It is currently unknown whether or not sirolimus drug-coated balloons (DCB) hold key advantages over paclitaxel DCB in the treatment of peripheral arterial disease. To determine if sirolimus-coated balloon angioplasty is non-inferior to paclitaxel-coated balloon angioplasty, researchers analyzed 482 participants across 25 clinical European sites with Rutherford category 2 to 4 femoropopliteal artery disease. The population of interest were randomized 1:1 to receive angioplasty with either a sirolimus-coated balloon or a paclitaxel&#8211;coated balloon.
The key efficacy end point of primary patency at 12 months was achieved in 73.8% of patients in the sirolimus DCB group compared with 75.0% in the paclitaxel DCB group. Moreover, the researchers noted that the rate of the composite primary safety outcome at 12 months of clinically driven target vessel revascularization (cdTVR), major amputation, or death was 9.4% in the sirolimus DCB compared with 7.3% in the paclitaxel DCB.
“This head-to-head comparison of sirolimus-coated balloons with paclitaxel-coated balloons during angioplasty of the femoropopliteal artery shows comparable results between the two study groups,” said Ulf Teichgräber, MD, MBA, MME, Department of Radiology, University Hospital Jena, Friedrich-Schiller-University Jena via a press release. “Understanding the safety and efficacy of these two types of balloons, especially compared to one another, can help provide the best patient care possible.”

Emily Menendez

Complete Response to Immunotherapy in HCC: Insights From IMbrave150

Hepatocellular Carcinoma

Anne Marie Morse, DO

Dr. Morse Talks About the Significance of World Sleep Day 2025

Sleep Disorders

Dr. John Fruehauf, Evolent

Advancing Therapies Have Improved the Prognosis of Metastatic Melanoma

Melanoma

Latest News

Sirolimus-Coated Balloons Yield Similar Efficacy to Paclitaxel-Coated Balloons in Treating PAD

TCT 2024

Sirolimus-coated balloons are non-inferior to paclitaxel-coated balloons in patients with PAD.

Sirolimus-Coated Balloons Yield Similar Efficacy to Paclitaxel-Coated Balloons in Treating Femoropop

About Us

Editorial Policy

Advertising

Contact Us

eNewsletters

Contribute

Career Center

MashupMD

Blood Cancers Today

Cancer Nursing Today

GU Oncology Now

Urban Health Today

Bile Duct Cancer

Colorectal Cancer

Gastroesophageal Cancer

Gastric Cancer

GEP-NETs

GIST

Liver Cancer

Pancreatic Cancer

GI Oncology Now

Anemia

Deep Vein Thrombosis

Essential Thrombocythemia

Hemophilia

Immune Thrombocytopenic Purpura

Myelodysplastic Syndromes

Myelofibrosis

Myeloproliferative Neoplasms

Polycythemia Vera

Pulmonary Embolism

Sickle Cell Disease

Thrombocytopenia

Thrombophilia

Thrombosis

Thrombotic Thrombocytopenic Purpura

Venous Thromboembolism

von Willebrand Disease

Heme Today

Acute Kidney Injury

ADPKD

Anemia and Kidney Disease

Chronic Kidney Disease

COVID-19 and Kidney Disease

Diabetes and Hypertension

End-Stage Renal Disease

Gout

Hyperkalemia

IgAN

Kidney Transplantation

Metabolic Acidosis

Nephrology Times

Mesothelioma

Non-Small Cell Lung Cancer

Small Cell Lung Cancer

Lung Cancers Today

Atherosclerotic Disease

Atrial Fibrillation

Heart Failure

Hypertension

Interventional Cardiology

Lipid Management

Practice Tips With Dr. Lichaa

Preventive Cardiology

Stroke

Cardiology

Breast Cancer

Gynecologic Cancer

Head and Neck Cancer

Skin Cancer

Oncology

Sleep

Urology

Diabetes

Ophthalmology

— Demodex Blepharitis

Neurology

Rheumatology

Gastroenterology

Pulmonology

Infectious Diseases

— HIV

Health and Wellness

Lupus

Future of Medicine

Orthopedics

Pharmacology

Career News

More

Conferences

CardioNerds

The Sleep Source With Dr. Morse

Rheumatology Rounds With Dr. Maheswaranathan

Partners

Expert Interviews

Subscribe